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Breaking the (Un)Sound Barrier: 
Filaggrin Is a Major Gene for Atopic 
Dermatitis
Alan D. Irvine1 and W.H. Irwin McLean2
We have recently shown that loss-of-function mutations in the filaggrin gene, 
carried by about 10% of people of European ethnicity, cause ichthyosis vul-
garis and are strong predisposing factors for atopic dermatitis and asthma 
secondary to atopic dermatitis. These results demonstrate a prominent role 
for the epidermal barrier in atopic disease and have important implications 
for the study of complex traits.
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Atopic dermatitis (AD) is one of the 
major problems in dermatology. It 
affects 15%–20% of children in devel-
oped nations and therefore represents 
an enormous burden on health care 
in general. AD has long been recog-
nized as a complex trait where a num-
ber of genetic factors interact with 
environmental stimuli to produce 
the disease. Because the condition 
is characterized by inflammation of 
the skin, a lot of effort has gone into 
potential immunological mechanisms 
in AD. With the advent of molecular 
genetics, a number of genetic loci 
for AD have been mapped over the 
past decade, but, as with many sto-
ries in complex-trait analysis, defini-
tively causative gene defects have 
been slow to emerge. More recently, 
a consensus has emerged that a bar-
rier defect is likely to be a primary 
event in AD (Taieb et al., 2006). This 
year, we identified the filaggrin gene 
(FLG) as a major player in AD, show-
ing that a heritable epidermal barrier 
defect is responsible in many cases 
of AD. As the common variants we 
have identified in this gene result in 
complete loss of filaggrin expression, 
as opposed to being polymorphisms 
of uncertain function, this represents 
hard evidence for a primary keratino-
cyte defect in a large proportion of AD. 
We first identified filaggrin mutations 
in ichthyosis vulgaris (IV), itself a very 
common keratinizing disorder (Smith 
et al., 2006). To our surprise, the two 
mutations we found in IV families, 
R501X and 2282del4, both of which 
lead to complete absence of filag-
grin expression (Figure 1), are carried 
by about 10% of people of European 
origin. Because many of our IV fami-
lies also had AD, we went on to show 
that AD is a transmissible monogenic 
trait with lower penetrance than IV in 
these families. Two association stud-
ies and a small prospective study gave 
extremely significant statistical asso-
ciation between these FLG mutations 
and AD. For example, in our pediatric 
AD cohort (Palmer et al., 2006), the χ2 
P value was 3 × 10–17. 
We also showed that FLG muta-
tions are a major risk factor for ecze-
ma-associated asthma, with lower 
penetrance than AD alone (Palmer et 
al., 2006). On the basis of our cur-
rent early data, we estimate that half 
or more of children with moderate to 
severe AD carry FLG mutations and 
that maybe as much as 20% of all 
asthma involves these gene defects, 
but, importantly, only asthma second-
ary to AD.
Filaggrin (filament-aggregating pro-
tein) was named by the late Peter 
Steinert, and its gene, FLG, is located 
with many others involved in terminal 
differentiation, in the epidermal dif-
ferentiation complex on chromosome 
1q21. As mapping of the epidermal 
differentiation complex was the work 
of the late Dietmar Mischke, we dedi-
cate this short paper to these eminent 
erstwhile colleagues, who were well 
known by keratinocyte biologists and 
readers of the Journal of Investigative 
Dermatology. The initial product of 
the FLG gene, profilaggrin, is a 400-
kilodalton polyprotein consisting of 
10–12 tandem repeats of the filaggrin 
peptide. Profilaggrin is the main con-
stituent of keratohyalin granules and, 
upon terminal differentiation, is proteo-
lytically cleaved into multiple copies 
of the 37-kilodalton filaggrin peptide. 
Filaggrin binds to and aggregates the 
keratin cytoskeleton, which in these 
upper granular cells has been strongly 
anchored to the cell membrane by 
increasing numbers of desmosomal 
proteins. Filaggrin collapses the cyto-
skeleton, resulting in flattening of kera-
tinocytes into squames. This condensed 
protein-lipid package is heavily cross-
linked by transglutaminases to form the 
epidermal barrier. Filaggrin has been 
suspected as the causative gene for IV 
for about 20 years, with compelling 
biochemical and genetic evidence in 
humans and mice, so why has it taken 
so long to uncover its role in this dis-
ease and AD? The main reason is that 
this gene has a very unusual structure 
that is particularly difficult to sequence 
routinely. Most of the coding sequences 
1Department of Paediatric Dermatology, Our Lady’s Hospital for Sick Children, Crumlin, Dublin, Ireland; 
and 2Epithelial Genetics Group, Human Genetics Unit, Division of Pathology and Neuroscience, Univer-
sity of Dundee, Ninewells Hospital & Medical School, Dundee, United Kingdom
Correspondence: Prof. Irwin McLean, Human Genetics Unit, Ninewells Hospital & Medical School, 
Dundee DD1 9SY, United Kingdom. E-mail w.h.i.mclean@dundee.ac.uk
|
We estimate that half 
or more of children 
with moderate to 
severe AD carry FLG 
mutations.
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are contained in the third and last giant 
exon, which is composed of 10–12 
almost perfect repeats about 1 kb in 
size, flanked by two additional imper-
fect repeats. Only a few isolated unique 
bases occur in each repeat that allow 
specific PCR, and in addition, we have 
found several of these to be polymor-
phic in the population, so that alleles 
can easily be lost during PCR. Some 
repeats contain no unique bases at all. 
Furthermore, there are size variants in 
the population, with some alleles hav-
ing 10, 11, or 12 repeats. Frances Smith 
was finally able to crack filaggrin, using 
methods she and one of us (W.H.I.M.) 
devised for the cloning and diagnos-
tic resequencing of the plectin gene 
in epidermolysis bullosa simplex with 
muscular dystrophy (McLean et al., 
1996). We can now routinely sequence 
about 90% of the filaggrin gene and are 
finding a range of IV- and AD-causing 
mutations other than the two common 
European variants.
Filaggrin deficiency in one in ten 
Europeans, or complete absence of 
filaggrin in one in 400, leads to mild 
or severe IV. These varying degrees of 
impaired keratinocyte differentiation 
and barrier formation allow increased 
transepidermal water loss and, impor-
tantly, increased entry of allergens, 
antigens, and chemicals from the 
environment. Thus, filaggrin-deficient 
individuals are chronically exposed to 
insult through the epidermis, which in 
many cases leads to inflammation of 
the skin — this is AD. We hypothesize 
that a percentage of these individuals 
go on to develop asthma when aller-
gens, to which their immune system 
has already been primed via cutane-
ous exposure, later enter the lungs; 
this is one possible mechanism of AD-
associated asthma.
Although this work confirms pre-
vious hypotheses of a primary bar-
rier dysfunction in AD, these genetic 
mutations are ancient and clearly can-
not explain the observed increase in 
AD and atopic disease in the past two 
decades. These recent increases in the 
prevalence of AD must be caused, at 
least in part, through environmental 
influences on the epithelial barrier. 
For example, different types of heat-
ing systems (Schafer et al., 1999) and 
low-humidity environments are likely 
to exacerbate the effects of filaggrin 
deficiency and increase susceptibility 
to develop AD (or lower the thresh-
old for developing it). Similar argu-
ments may be advanced regarding 
hard-water areas, increased use of 
detergents, environmental pollutants, 
increased washing, and many other 
influences. A corollary is that cur-
rent efforts to intervene early and to 
potentially prevent the “atopic march” 
(Hahn and Bacharier, 2005) are now 
supported by additional evidence that 
warrants a focus on improving bar-
rier dysfunction. Although the precise 
population attributable risk of these 
mutations to AD and asthma will 
require replication and clarification in 
other cohorts, including longitudinal 
studies, it seems likely that carriers of 
FLG null alleles will represent a signif-
icant proportion of the at-risk popula-
tion for AD and associated asthma. If 
early intervention measures in at-risk 
atopic children are shown to be effec-
tive, screening for FLG null alleles 
may well represent one mechanism 
of identifying cohorts likely to benefit 
from such measures.
Two independent genetic mecha-
nisms have given rise to an epithelial 
barrier defect in around 10% of peo-
ple of European origin. This frequency 
is not easily explained by genetic drift. 
The simultaneous emergence of these 
two functional polymorphisms to simi-
lar carrier frequencies of approximate-
ly 5% is consistent with the balanced 
selection that is seen where there is 
a heterozygote advantage. Similar 
mechanisms are widely accepted to 
underlie the simultaneous emergence 
of different sickle-cell anemia muta-
tions, under selection pressure by con-
ferring resistance to malaria, and are 
postulated for resistance to Salmonella 
infections in carriers of cystic fibro-
sis mutations. Could a minor barrier 
defect hold, or historically have held, 
an evolutionary advantage in European 
populations? One mechanism for this 
advantage might be through repeated 
low-level exposure of pathogens to 
epithelial antigen-presenting cells, 
effecting a “natural vaccination” and 
conferring increased immunity to 
infections such as tuberculosis, influ-
enza, or even the plague. Is atopic 
disease a modern plague suffered by 
descendants of the survivors of ancient 
plagues? Although we have focussed 
on European populations, it seems 
likely that Asian and African popula-
tions will also have recurrent muta-
tions in FLG. The population genetics 
of FLG mutations in these and other 
populations will be fascinating.
An important lesson has emerged 
from this work: we should not com-
pletely neglect monogenic mende-
lian disorders in the quest for genes 
Figure 1. Homozygous FLG mutations lead to complete loss of filaggrin expression in skin. 
Immunostaining with filaggrin repeat domain mAb 15C10 (Novocastra, Newcastle upon Tyne, United 
Kingdom) shows the abundant keratohyalin granules present in normal epidermis (left) In contrast, the 
granular layer is absent in an individual homozygous for a loss-of-function mutation in the filaggrin gene 
(right). This teenage individual is affected by ichthyosis vulgaris and also has had moderate to severe 
atopic dermatitis since infancy.
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involved in complex traits. A recent 
review article makes this point and 
goes on to show that, surprisingly, the 
rate of discovery of disease genes has 
actually decreased since the genome 
was completed, even though posi-
tional cloning and positional can-
didate genetics are easier than ever 
before (Antonarakis and Beckmann, 
2006). Part of the reason is that fund-
ing agencies and, presumably, a good 
number of peer reviewers regard rare 
mendelian traits as easy to solve and 
not worthy of funding. The fact of the 
matter is that most disease genes, 
including many involved in complex 
traits or cancer, have emerged from 
monogenic disorders. For example, 
the patched gene was identified by 
study of the very rare Gorlin syndrome 
but is a major player in basal-cell car-
cinoma, the most common human 
cancer. We accept that filaggrin is an 
unusual example of the genre, and 
we agree that a large-scale approach 
to complex traits is required, but we 
would suggest that a more balanced 
view be taken, as so much of what 
we know about basic genetic mecha-
nisms underlying both common and 
rare disorders continues to come from 
the mendelian camp.
Our work on filaggrin has firm-
ly established an important role of 
the keratinocyte and the epidermal 
barrier formation in atopic derma-
titis. As the epidermal differentia-
tion complex locus on 1q21 is also 
known to harbor a psoriasis suscep-
tibility gene (Bowcock and Cookson, 
2004), we posit that a barrier defect 
is also involved in this complex trait. 
Furthermore, an autosomal dominant 
form of the follicular occlusion dis-
order hidradenitis suppurativa was 
recently linked to a large interval con-
taining the epidermal differentiation 
complex (Gao et al., 2006). Thus, the 
importance of maintaining a sound 
barrier in the skin and its appendages 
may come to the fore in genoderma-
tology in the near future.
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Epidermal Differentiation Complex 
Yields a Secret: Mutations in the 
Cornification Protein Filaggrin 
Underlie Ichthyosis Vulgaris
Julia A. Segre1
Ichthyosis vulgaris (IV), characterized by mild scaling on limbs and lower 
abdomen, has an incidence of 1 in 250. Smith, McLean, and colleagues dem-
onstrate that common mutations in filaggrin underlie IV. Filaggrin aggregates 
keratin intermediate filaments and is cross-linked into the cornified envelope 
to form the epidermal barrier. These findings reinforce the importance of the 
epidermal barrier in pathogenesis of skin diseases.
Journal of Investigative Dermatology (2006) 126, 1202–1204. doi:10.1038/sj.jid.5700367
Ten years ago the phrase “epidermal 
differentiation complex” (EDC) was 
first coined in this journal to describe 
the 1.6-Mb locus on human chromo-
some 1q21 that contains more than 30 
genes encoding both epidermal corni-
fication and S100 proteins (Mischke 
et al., 1996). Now, finally, the EDC 
has revealed one of its most guarded 
secrets: Resident in this gene com-
plex is the cause of the very common 
skin disorder ichthyosis vulgaris (IV) 
(OMIM 146700). In a recent report in 
Nature Genetics, Smith, McLean, and 
colleagues have convincingly dem-
onstrated that mutations in the gene 
encoding filaggrin (FLG), the keratin 
filament-aggregating protein, under-
lie IV (Smith et al., 2006). Twenty 
years ago, a defect in the synthesis 
of FLG was observed in IV patients 
(Sybert et al., 1985). Four years ago, 
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